Role of hypoxia-inducible factor-1 in immune escape of tumor cells

doi:10.16098/j.issn.0529-1356.2016.06.025

Abstract

Abstract:

Hypoxia is a hallmark of tumor, and hypoxia-inducible factor (HIF-1) is an essential regulator of hypoxia adaptation in tumor progression. Hypoxia and HIF-1 signaling are important components of the tumor microenvironment that modulates the tumor immune response. Tumor hypoxia via HIF-1 signaling enables tumor cell to develop mechanisms to evade from immune surveillance and attack. This mini-review emphasizes on the molecular mechanisms of HIF-1-mediated tumor cell escape and the development of inhibitors targeting HIF-1.

Key words: Hypoxia-inducible factor 1, Tumor, Immune escape

XIONG Wei-peng. Role of hypoxia-inducible factor-1 in immune escape of tumor cells[J]. Acta Anatomica Sinica, 2016, 47(6): 859-961.

References

［1］LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology ［J］. Nat Cell Biol, 2016, 18(4):356-365.

［2］Rankin EB, Giaccia AJ. Hypoxic control of metastasis ［J］. Science, 2016, 352(6282):175-180.

［3］Pouyssequr J, Dayan F, Mazure NM. Hypoxia signaling in cancer and approaches to enforce tumour regression ［J］. Nature, 2006, 441(7092):437-443.

［4］Barsoum IB, Koti M, Siemens DR, et al. Mechanisms of hypoxia-mediated immune escape cancer ［J］. Cancer Res, 2014, 74(24):7185-7190.

［5］Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects ［J］. Nat Rev Immunol, 2004, 4(12):941-952.

［6］Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment ［J］. Carcinogenesis, 2009, 30(3):377-386.

［7］Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression ［J］. Cancer Meta Rev, 2007, 26(3-4):525-534.

［8］Whiteside TL, Mandapathil M, Schuler P. The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg) ［J］. Curr Med Chem, 2011, 18(34):5217-5223.

［9］Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor ［J］. J Clin Invest, 2003, 111(5):727-735.

［10］Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells ［J］. Cancer Res, 2008, 68(13):5439-5449.

［11］Barsoum IB, Hamilton TK, Li X, et al. Hypoxia induces escape from innate immunity in cancer cells viaincreased expression of ADAM10: role of nitric oxide ［J］. Cancer Res, 2011, 71(24):7433-7441.

［12］Barsoum IB, Smallwood CA, Siemens DR, et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells ［J］. Cancer Res, 2014, 74(3):665-674.

［13］Wu AA, Drake V, Huang HS, et al. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells ［J］. Oncoimmunology, 2015, 4(7):1-14.

［14］Medina PJ, Adams VR. PD-1 pathway inhibitors: immune-oncology agents for restoring antitumor immune responses ［J］. Pharmacotherapy, 2016, 36(3):317-334.

［15］Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications ［J］. Nat Rev Clin Oncol, 2016, 13(4):209-227.

［16］Zhang H, Lu H, Xiang L, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells ［J］. Proc Natl Acad Sci USA, 2015, 112(45):E6215-6223.

［17］Jardon MA, Rothe K, Bortnik S, et al. Autophagy: from structure to metabolism to therapeutic regulation ［J］. Autophagy, 2013, 9(12):2180-2182.

［18］Paggetti J, Viry E, Berchem G, et al. Hypoxia-induced autophagy in tumor cells: a key target for improving cancer immunotherapy ［J］. Cancer Cell & Microenviron, 2014, 1(e213):1-5.

［19］Ajdukovic J. HIF-1-a big chapter in the cancer tale ［J］. Exp Oncol, 2016, 38(1):9-12.

［20］Miranda E, Nordgren IK, Male AL, et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells ［J］. J Am Chem Soc, 2013, 135(28):10418-10425.

［21］Masoud GN, Li W. HIF-1αpathway: role, regulation and intervention for cancer therapy ［J］. Acta Pharm Sin B, 2015, 5(5):378-389.

［22］Zhao T, Ren H, Jia L, et al. Inhibition of HIF-1αby PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma ［J］. Oncotarget, 2015, 6(4):2250-2262.

［23］Santoni M, Pantano F, Amantini C, et al. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma ［J］. Biochim Biophys Acta, 2014, 1845(2):221-231.

［24］Karim SM, Zekri J. Chemotherapy for small cell lung cancer: a comprehensive review ［J］. Oncol Rev, 2012, 6(1):16-36.

［25］Trafalis DT, Alifieris C, Stathopoulos GP, et al. Phase Ⅱ study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer ［J］. Cancer Chemother Pharmacol, 2016, 77(4):713-722.

[1]	HOU Yi-wei YANG Yu WANG Bo DUAN Ying-tao YAO Hong-bo. Effects of pranlinide on cognitive behavior, β amyloid protein 6E10, inflammatory factors and neuronal cell morphology in brain and retina of 5×FAD mice and WT mice [J]. Acta Anatomica Sinica, 2023, 54(3): 283-288.
[2]	LI Wei YANG Gan-un PENG Jian-an HU Hong-mei ZHOU Xing-chen . Effect of tumor necrosis factorα overexpress on the biological properties dental pulp stem cells in microoxidative stress [J]. Acta Anatomica Sinica, 2022, 53(1): 66-74.
[3]	YANG Chen-chen FAN Yu-qin . Relationship between miR-26a and metadherin and the verification of tumor-bearing experiment in nude mice [J]. Acta Anatomica Sinica, 2022, 53(1): 82-91.
[4]	TAN Xue-ming ZHAO Ran SUN Yong-zhen GAO Xiao-yan ZHAO Peng WANG Yan ZHU Min LI Wei-dong. Endoscopic ultrasonography improving the operation effect for detecting precisely the origin and histology characteristics of esophageal leiomyoma [J]. Acta Anatomica Sinica, 2021, 52(6): 966-971.
[5]	GAO Fei ZHANG Xin-xin YANG Bing CHEN Su-zhi YANG Feng-wen TAN Miao TAN Jin-chuan. MicroRNA-193a regulating Wilms’tumor gene 1 to promote mouse podocyte apoptosis in diabetic nephropathy#br# [J]. Acta Anatomica Sinica, 2021, 52(5): 728-736.
[6]	SU Hao REN Jie QIN Li-hua. Suppressing and activating effects of Nogo-B receptors in the pathogenesis of malignant solid tumors [J]. Acta Anatomica Sinica, 2021, 52(3): 489-494.
[7]	YIN Xue-yan GUO Shao-kai TAN Jun FAN Wen-tong LI Ming. Effcts of adenosine preconditioning on the expression of tumor necrosis factor α and nuclear factor κB in rats after cerebral ischemia-reperfusion injury [J]. Acta Anatomica Sinica, 2020, 51(6): 839-847.
[8]	HE Qi ZHAO Wei ZHANG Zhi-qian. Suppression of stem cell-like properties of human hepatocellular carcinoma cell line Hep-12 using the clustered regularly interspaced short palindromic repeats/associated protein 9 system [J]. Acta Anatomica Sinica, 2020, 51(6): 882-887.
[9]	LIN Chen MA Qi WANG Ping. Coronin，a novel potential target in tumor [J]. Acta Anatomica Sinica, 2020, 51(3): 461-468.
[10]	LIU Ya-jun WANG Xuan HU Hai GUI Yan. Effect and mechanism of rosuvastatin preconditioning on inflammatory cytokines release in vascular smooth muscle cells of middle cerebral artery of rats after focal cerebral ischemia-reperfusion [J]. Acta Anatomica Sinica, 2019, 50(6): 713-717.
[11]	BIAN Xiao-cui LIU Yu-qin YANG Zhen-li FENG Hai-liang. Troubles and answers of identity authentication of human tumor cell lines established in China [J]. Acta Anatomica Sinica, 2019, 50(2): 201-210.
[12]	CHANG Shu-feng YANG Bo ZHENG Lu FU Zhan-sheng YANG Wan-jing HUANG Xiao-feng WANG Jun-shan LIU Chang. Microanatomy of suboccipital retrosigmoid keyhole approach via petrosal fissure and cerebello-pontine fissure [J]. Acta Anatomica Sinica, 2018, 49(5): 646-650.
[13]	XU Xiang-liang SUN Zhi-peng WANG Dian-can WANG Jian-wei ZHANG Wei-guang. Clinical anatomy of parotid surface division associated with tumorigenesis [J]. Acta Anatomica Sinica, 2018, 49(1): 75-80.
[14]	SONG Ya-qiong ZHOU Bo-jiang. Recent progress on the mechanism of energy metabolism of hypoxia-inducible factor 1-driven skeletal muscle adaptations to hypoxia [J]. Acta Anatomica Sinica, 2017, 48(2): 236-240.
[15]	TANG Hai-jun LIU Yu-qin. Development of chimeric antigen receptor modified T cells and the selection of tumor target antigen [J]. Acta Anatomica Sinica, 2017, 48(1): 115-120.